Success Metrics

Clinical Success Rate
83.3%

Based on 10 completed trials

Completion Rate
83%(10/12)
Active Trials
1(7%)
Results Posted
70%(7 trials)
Terminated
2(13%)

Phase Distribution

Ph not_applicable
1
7%
Ph phase_2
9
60%
Ph phase_1
3
20%
Ph early_phase_1
1
7%
Ph phase_3
1
7%

Phase Distribution

4

Early Stage

9

Mid Stage

1

Late Stage

Phase Distribution15 total trials
Early Phase 1First-in-human
1(6.7%)
Phase 1Safety & dosage
3(20.0%)
Phase 2Efficacy & side effects
9(60.0%)
Phase 3Large-scale testing
1(6.7%)
N/ANon-phased studies
1(6.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

15

all time

Status Distribution
Active(1)
Completed(10)
Terminated(2)
Other(2)

Detailed Status

Completed10
Terminated2
unknown1
Recruiting1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
1
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (6.7%)
Phase 13 (20.0%)
Phase 29 (60.0%)
Phase 31 (6.7%)
N/A1 (6.7%)

Trials by Status

unknown17%
recruiting17%
terminated213%
completed1067%
suspended17%

Recent Activity

1 active trials
Showing 5 of 15
suspendedphase_2

Testing Obeticholic Acid for Familial Adenomatous Polyposis

NCT05223036
recruitingphase_2

Obeticholic Acid for Prevention in Barrett's Esophagus

NCT04939051
terminatedphase_2

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

NCT04594694
terminatedphase_3

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

NCT02548351
completedphase_2

Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients

NCT02430077
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT05223036Phase 2

Testing Obeticholic Acid for Familial Adenomatous Polyposis

Suspended
NCT04939051Phase 2

Obeticholic Acid for Prevention in Barrett's Esophagus

Recruiting
NCT04594694Phase 2

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Terminated
NCT02548351Phase 3

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

Terminated
NCT02430077Phase 2

Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients

Completed
NCT01585025Phase 2

Obeticholic Acid in Bile Acid Diarrhoea

Completed
NCT05133830Phase 1

Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants

Completed
NCT01865812Phase 2

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

Completed
NCT03836937Not Applicable

Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT

Completed
NCT02532335Phase 1

Obeticholic Acid in Morbidly Obese Patients and Healthy Volunteers

Unknown
NCT04053023Phase 1

Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects

Completed
NCT03253276Early Phase 1

Effect of Obeticholic Acid on Transport of Bile Acids in PBC Examined by 11C-cholyl-sarcosine PET/CT

Completed
NCT02633956Phase 2

Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)

Completed
NCT01265498Phase 2

The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)

Completed
NCT01625026Phase 2

Obeticholic Acid in Bariatric and Gallstone Disease

Completed

All 15 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
15